BBOT — BridgeBio Oncology Therapeutics, Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 1869105 ·
Last close
$8.55
Market Cap
$684.92M
52W High
$11.02
52W Low
$7.60
ADV30
488,377
Next earnings
2026-08-11
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -46,179,000 -42,106,000 417,646,000 52,658,000 45,366,000
Dec 2025 0 -43,408,000 -38,797,000 448,381,000 373,687,000 37,285,000
Sep 2025 0 -49,181,000 -44,757,000 484,793,000 408,741,000 38,093,000
Jun 2025 0 -30,093,000 -28,435,000 151,253,000 31,518,000 378,986,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-113,894,000
Investing CF
$73,328,000
Financing CF
$383,402,000
CapEx
$-606,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-2.16
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-356,567,000
Inventory
Receivables
$386,000
ST Investments
$51,773,000
EBIT TTM
$-145,819,000
Pretax Income TTM
$-134,044,000
Interest Exp TTM
Analysts
8

Annual Trend (SEC EDGAR, last 3y)

Revenues vs Net Income (last 3y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -145,819,000 -134,044,000 448,381,000 37,285,000 -113,894,000
Dec 2024 0 -80,863,000 -74,275,000 164,301,000 342,938,000 -55,027,000
Dec 2023 0 -64,771,000 -64,699,000 5,942,000 121,583,000 -52,079,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-2.14

Peers — same industry

TickerNameMarket CapLastDaily %
DSGN Design Therapeutics, Inc. $685.15M $10.97
ANL Adlai Nortye Ltd. $700.12M $11.92
PAHC PHIBRO ANIMAL HEALTH CORP $700.74M $33.26
CYRX Cryoport, Inc. $705.63M $14.00
MRVI MARAVAI LIFESCIENCES HOLDINGS, INC. $649.03M $4.40

News headlines (Yahoo Finance, 1h cache)

Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
2026-05-17 18:33 · Yahoo
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally
2026-05-17 18:25 · Yahoo
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More
2026-05-17 18:18 · Yahoo
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet
2026-05-15 23:02 · Yahoo
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back
2026-05-15 22:56 · Yahoo
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares
2026-05-15 22:50 · Yahoo
BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
2026-05-12 21:03 · Yahoo
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-05-12 20:05 · Yahoo
Here Are Monday’s Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy’s, and More
2026-05-11 11:58 · Yahoo
Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics
2026-04-24 10:46 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.